Perrigo Reports $1.4 Billion Net Loss Driven by Massive Goodwill Impairment, Warns of Further Impairments

summarizeSummary

Perrigo reported a $1.43 billion net loss for 2025, primarily due to a $1.33 billion goodwill impairment, with further impairments expected in Q1 2026. The company faces ongoing challenges in its infant formula business and a recent credit rating downgrade.

check_boxKey Events

• Massive Goodwill Impairment Charge

  Perrigo recognized a goodwill impairment of $1.33 billion in Q4 2025, with $917.1 million attributed to Consumer Self-Care Americas (CSCA) and $407.1 million to Consumer Self-Care International (CSCI). This was driven by a sustained decrease in share price, lower expected cash flows from infant formula, and a change in broader self-care market expectations. This adds new details to the prior 8-K filing on the same day.

• Anticipated Future Impairment

  The company estimates additional structural non-cash goodwill impairment charges of up to $350 million in Q1 2026 due to a planned segment reorganization from a geographic to a category-based view.

• Significant Net Loss and EPS Decline

  Perrigo reported a net loss of $1.43 billion for 2025, a substantial increase from a $171.8 million loss in 2024. Basic and diluted EPS also worsened significantly to $(10.29) in 2025 from $(1.25) in 2024.

• Infant Formula Business Challenges

  The infant formula business continues to face significant headwinds, including FDA warning letters and inspection observations (a new Form 483 was issued in February 2026), increased production costs, reduced volumes, and lost distribution. A strategic review of this business was announced in November 2025.

auto_awesomeAnalysis

Perrigo Company plc reported a substantial net loss of $1.43 billion for fiscal year 2025, primarily driven by a significant $1.33 billion goodwill impairment charge. This impairment reflects challenges in the infant formula market and a revised outlook for the broader self-care market. The company also anticipates additional non-cash goodwill impairment charges of up to $350 million in the first quarter of 2026 due to a segment reorganization. These financial setbacks are compounded by an ongoing strategic review of the infant formula business, which has faced regulatory scrutiny and lost distribution. The recent credit rating downgrade by Moody's will also lead to increased interest expenses. While the company has implemented operational efficiency programs and plans a divestiture to generate cash, the magnitude of the impairments and persistent business challenges signal a difficult period ahead, impacting the company's asset base and future profitability.